ACTUATE THERAPEUTICS, INC. 10-Q

Actuate Therapeutics, Inc. 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-42139 Actuate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 47-3044785 (I.R.S. Employer Identification No.) 1751 River Run , Suite 400 , Fort Worth , Texas (Address of principal executive offices) 76107 (Zip Code) Registrant’s telephone number, including area code: ( 817 ) 887-8455 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, par value $0.000001 per share ACTU The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý NO ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý NO ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ý Smaller reporting company ý Emerging growth company ý If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ý On August 13, 2026, 24,014,202 shares of common stock, $0.000001 par value per share, were outstanding. INDEX Page PART I - FINANCIAL INFORMATION Item 1. Financial Statements 1 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation s 16 Item 3. Quantitative and Qualitative Disclosures About Market Risk 25 Item 4. Controls and Procedures 25 PART II - OTHER INFORMATION Item 1A. Risk Factors 26 Item 5. Other Information 27 Item 6. Exhibits 27 SIGNATURES 28 i Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to “Actuate,” the “Company,” “we,” “us,” and “our” refer to Actuate Therapeutics, Inc. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (“Report” or “Quarterly Report”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") about us and our industry. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in them. The forward-looking statements in this Report include, but are not limited to, statements concerning the following: · our expectations for the results of our clinical and nonclinical studies of elraglusib and any future product candidates we may choose to pursue, including any modifications to clinical development plans based on feedback that we may receive from regulatory authorities; · our regulatory plans to seek feedback from the U.S. Food and Drug Administration (the “FDA”) or European Medicines Agency (“EMA”) in 2026 on the design and execution of clinical studies, including the Phase 1/2 clinical study in advanced cancer patients using the oral tablet formulation of elraglusib and the design of a future clinical studies of elraglusib for the treatment of mPDAC and potentially other cancers using the oral tablet formulation of elraglusib; · our ability to enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA; · our ability to successfully manage our relationships with our licensors and third-party service providers; · our ability to maintain, protect and further develop our intellectual property rights; · our ability to fund our current operations with our cash on hand as of the date of this Report and our ability to raise additional capital as and when needed; · our future financial and operating results; · our intentions, expectations and beliefs regarding anticipated growth, market penetration and trends in our business; · our ability to maintain the listing of our common stock on the Nasdaq Global Market; and · the timing and success of our plan of commercialization. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those risk factors identified in Part II, Item 1A. “Risk Factors” in this Report and under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 26, 2026. You should assume that the information appearing in this Report is accurate as of its date only. Because the risk factors referred to above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. All written or oral forward-looking statements attributable to us or any person acting on our behalf made after the date of this Report are expressly qualified in their entirety by the risk factors and cautionary statements contained in this Report. Unless legally required, we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this Report or to reflect the occurrence of unanticipated events. In addition, statements that “we believe” and similarly qualified statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon them. The discussion of the Company’s financial condition and results of operations should be read in conjunction with the Company’s consolidated financial statements and the related notes thereto included in this Report. ii PART I - FINANCIAL INFORMATION Item 1. Financial Statements Actuate Therapeutics, Inc. Condensed Consolidated Balance Sheets June 30, 2026 December 31, 2025 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 4,425,841 $ 13,159,423 Prepaid assets and other current assets 322,100 483,996 Total current assets 4,747,941 13,643,419 Deferred offering costs and other assets 451,398 392,491 Total assets $ 5,199,339 $ 14,035,910 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 1,076,691 $ 1,524,190 Other accrued expenses 2,304,621 3,567,404 Accrued compensation 386,741 588,304 Accrued interest, current 37,143 27,018 Total current liabilities 3,805,196 5,706,916 Long term liabilities: License payable 404,991 404,991 Total long-term liabilities 404,991 404,991 Total liabilities 4,210,187 6,111,907 Commitments and contingencies (Note 4) – Stockholders’ equity: Preferred stock, $ 0.000001 par value, 10,000,000 shares authorized, no shares issued or outstanding – – Common stock, $ 0.000001 par value, 200,000,000 shares authorized, 24,013,577 and 23,245,203 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively 24 23 Additional paid-in capital 166,089,213 162,531,681 Accumulated deficit ( 165,100,085 ) ( 154,607,701 ) Total stockholders’ equity 989,152 7,924,003 Total liabilities and stockholders’ equity $ 5,199,339 $ 14,035,910 See accompanying notes to unaudited condensed consolidated financial statements. 1 Actuate Therapeutics, Inc. Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Operating expenses: Research and development $ 2,066,825 $ 2,764,805 $ 4,632,069 $ 5,985,124 General and administrative 2,839,763 3,204,072 5,980,475 6,349,337 Total operating expenses 4,906,588 5,968,877 10,612,544 12,334,461 Loss from operations ( 4,906,588 ) ( 5,968,877 ) ( 10,612,544 ) ( 12,334,461 ) Other income (expense): Interest expense ( 5,063 ) ( 5,062 ) ( 10,125 ) ( 10,125 ) Interest income 45,016 24,534 130,285 78,157 Total other income, net 39,953 19,472 120,160 68,032 Net loss $ ( 4,866,635 ) $ ( 5,949,405 ) $ ( 10,492,384 ) $ ( 12,266,429 ) Weighted-average shares of common stock outstanding, basic and diluted 23,871,850 19,646,475 23,705,417 19,572,564 Net loss per share attributable to common stockholders, basic and diluted $ ( 0.20 ) $ ( 0.30 ) $ ( 0.44 ) $ ( 0.63 ) See accompanying notes to unaudited condensed consolidated financial statements. 2 Actuate Therapeutics, Inc. Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) For the Six Months Ended June 30, 2026 Additional Total Common Stock Paid-in Accumulated Stockholders’ Shares Amount Capital Deficit Equity Balances, January 1, 2026 23,245,203 $ 23 $ 162,531,681 $ ( 154,607,701 ) $ 7,924,003 Issuance of shares under At-the-Market facility, net of issuance costs of $ 13,977 198,793 – 518,971 – 518,971 Issuance of vested and settled restricted stock units 339,555 1 ( 1 ) – – Shares of common stock withheld related to net settlement of restricted stock units ( 121,874 ) – ( 527,716 ) – ( 527,716 ) Issuance of restricted shares in exchange for services 50,000 – 138,500 – 138,500 Stock-based compensation expense – – 1,356,389 – 1,356,389 Net loss – – – ( 5,625,749 ) ( 5,625,749 ) Balances, March 31, 2026 23,711,677 24 164,017,824 ( 160,233,450 ) 3,784,398 Issuance of shares under At-the-Market facility, net of issuance costs of $ 40,118 299,400 – 730,620 – 730,620 Issuance of vested and settled restricted stock units 2,500 – – – – Stock-based compensation expense – – 1,340,769 – 1,340,769 Net loss – – – ( 4,866,635 ) ( 4,866,635 ) Balances, June 30, 2026 24,013,577 $ 24 $ 166,089,213 $ ( 165,100,085 ) $ 989,152 3 For the Six Months Ended June 30, 2025 Total Additional Stockholders’ Common Stock Paid-in Accumulated Equity Shares Amount Capital Deficit (Deficit) Balances, January 1, 2025 19,531,636 $ 20 $ 132,484,015 $ ( 132,379,849 ) $ 104,186 Stock-based compensation expense – – 1,125,101 – 1,125,101 Net loss – – – ( 6,317,024 ) ( 6,317,024 ) Balances, March 31, 2025 19,531,636 20 133,609,116 ( 138,696,873 ) ( 5,087,737 ) Issuance of shares under June 2025 Private Placement, net of issuance costs of $ 43,933 666,497 – 4,621,546 – 4,621,546 Issuance of shares under Committed Equity Facility, net of issuance costs of $ 343,848 256,429 – 2,148,506 – 2,148,506 Exercise of stock option awards 15,942 – 34,115 – 34,115 Stock-based compensation expense – – 1,579,271 – 1,579,271 Net loss – – – ( 5,949,405 ) ( 5,949,405 ) Balances, June 30, 2025 20,470,504 $ 20 $ 141,992,554 $ ( 144,646,278 ) $ ( 2,653,704 ) See accompanying notes to unaudited condensed consolidated financial statements. 4 Actuate Therapeutics, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) Six Months Ended June 30, 2026 2025 Operating Activities: Net loss $ ( 10,492,384 ) $ ( 12,266,429 ) Adjustment to reconcile net loss to net cash used in operating activities: Stock-based compensation expense 2,697,158 2,704,372 Issuance of restricted shares in exchange for services 138,500 – Interest accrued on license payable 10,125 10,125 Changes in operating assets and liabilities: Prepaid assets and other current assets 161,896 370,375 Other assets – 110,548 Accounts payable ( 473,399 ) 1,130,116 Accrued compensation ( 201,563 ) 499,669 Other accrued expenses ( 1,262,783 ) ( 1,351,277 ) Net cash used in operating activities ( 9,422,450 ) ( 8,792,501 ) Financing Activities: Proceeds from sale of shares under At-the-Market Facility, net 1,251,213 – Payment of taxes from withholding of common stock on settlement of restricted stock units ( 527,716 ) – Proceeds from issuance of shares of common stock under June 2025 Private Placement, net of issuance costs of $ 43,933 – 4,621,546 Proceeds from issuance of shares of common stock under the Committed Equity Facility, net of issuance costs of $ 343,848 – 2,163,100 Proceeds from the exercise of stock options – 34,115 Deferred offering costs ( 34,629 ) ( 175,226 ) Net cash provided by financing activities 688,868 6,643,535 Net change in cash and cash equivalents ( 8,733,582 ) ( 2,148,966 ) Cash and cash equivalents, beginning of period 13,159,423 8,641,622 Cash and cash equivalents, end of period $ 4,425,841 $ 6,492,656 Supplemental disclosure of cash flow information: Cash paid for interest $ – $ – Cash paid for income taxes $ 800 $ 800 Supplemental Schedule of Noncash Financing Activities: Deferred offering costs charged against At-the-Market Facility $ 1,622 $ – Deferred offering costs, unpaid and accrued $ 25,900 $ 119,710 Deferred offering costs charged against Committed Equity Facility $ – $ 14,594 See accompanying notes to unaudited condensed consolidated financial statements. 5 Actuate Therapeutics, Inc. Notes to the Condensed Consolidated Financial Statements For The Three and Six Months Ended June 30, 2026 (unaudited) 1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Actuate Therapeutics, Inc. (the “Company”) was incorporated in the State of Delaware on January 16, 2015 and is headquartered in Fort Worth, Texas. The Company is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of cancers through the inhibition of glycogen synthase kinase-3 (“GSK-3”). The Company’s lead investigational product, elraglusib (formerly 9-ING-41), is a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, thereby causing the death of the cancer cells and the regulation of anti-tumor immunity. The Company has a 100%-owned Irish subsidiary, Actuate Therapeutics Limited, that is currently dormant. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements include only normal and recurring adjustments that the Company believes are necessary to fairly state the Company’s financial position and the results of its operations and cash flows. Operating results for the three and six months ended June 30, 2026 are not necessarily indicative of the results expected for the full fiscal year or any subsequent interim period. The condensed consolidated balance sheet at December 31, 2025 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP for complete financial statements. Because all of the disclosures required by U.S. GAAP for complete financial statements are not included herein, these unaudited condensed consolidated financial statements and the notes accompanying them should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 26, 2026. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). Going Concern and Management’s Plans The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. As of June 30, 2026, the Company had cash and cash equivalents of $ 4,425,841 and working capital of $ 942,745 . The Company has not generated any revenue and has incurred recurring operating losses since inception. The Company expects to continue to incur losses for the foreseeable future and therefore the Company’s ability to continue its operations is highly dependent on its ability to raise additional capital in the near term to fund its future operations. On November 28, 2025, the Company entered into an At Market Issuance Sales Agreement (the “ATM Agreement”) with B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC (each a “Sales Agent” and collectively the “Sales Agents”) with respect to an “at the market” offering program (the “ATM Facility”), under which the Company may, from time to time, at its sole discretion, issue and sell through the Sales Agents, up to $100 million of shares of common stock. Pursuant to the ATM Agreement, the Company may sell the shares through the Sales Agents by any method permitted that is deemed an “at the market” offering as defined in Rule 415 under the Securities Act. The Sales Agents will use commercially reasonable efforts consistent with their normal trading and sales practices to sell the shares from time to time, based upon instructions from us, including any price or size limits or other customary parameters or conditions we may impose. The Company will pay the Sales Agents a commission of up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the ATM Agreement and also has provided the Sales Agents with customary indemnification rights. During the six months ended June 30, 2026, the Company sold 498,193 shares of common stock at a weighted-average price of $2.66 per share, for net proceeds of $ 1,249,591 under the ATM Facility. As of June 30, 2026, the Company had approximately $ 98.7 million in remaining capacity under its ATM Facility (see Note 6). 6 On March 27, 2025, the Company entered into a common stock purchase agreement (the “Committed Equity Facility”) with B. Riley Principal Capital II (“B. Riley”) giving the Company the right, but not the obligation, to sell to B. Riley over a 36-month period up to the lesser of (i) $50 million of newly issued shares of our common stock and (ii) 3,904,374 shares of the Company’s common stock (see Note 6). The price per share of common stock sold to B. Riley is determined by reference to the volume-weighted average price of the Company’s common stock as defined within the Committed Equity Facility, less a 3% discount, subject to certain limitations and conditions. The total net proceeds that the Company will receive under the Committed Equity Facility will depend on the quantity, frequency, and prices at which the Company sells common stock to B. Riley. During the six months ended June 30, 2026, the Company did no t issue any shares of common stock under the Committed Equity Facility (see Note 6). There can be no assurance that the Company will be able to raise sufficient proceeds in the future under the ATM Facility or the Committed Equity Facility, or that any other financing will be available to the Company on acceptable terms, if at all. Management anticipates, based on currently proposed plans and assumptions, that our cash and cash equivalents on hand will not satisfy the Company’s operational and capital requirements beyond September 2026 without raising additional capital. As the Company executes its business plan, it plans to seek financing for its operations through equity offerings, debt financings, or other capital sources. The Company’s ability to raise additional capital may be adversely impacted by business conditions, global economic conditions, disruptions to, and volatility in, the financial markets in the United States and worldwide, among other matters, and it may not obtain this necessary capital when needed on acceptable terms, or at all. If events or circumstances occur such that the Company does not obtain additional funding, it may be necessary to significantly reduce our scope of operations to reduce the current rate of spending through actions such as the need to delay, limit, reduce, grant rights to develop or terminate its product development or even cease operations, which could have a material adverse effect on the Company’s business, results of operations or financial condition. Based on the above matters, we have concluded that there is substantial doubt regarding the Company’s ability to continue as a going concern. 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company’s significant accounting policies are disclosed in the audited financial statements and the notes thereto for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 26, 2026. Since the date of such audited consolidated financial statements, there have been no changes to the Company’s significant accounting policies. Principles of Consolidation The consolidated financial statements include the accounts of Actuate Therapeutics, Inc. and its wholly owned subsidiary, Actuate Therapeutics Limited. All material intercompany accounts and transactions have been eliminated in the consolidated financial statements. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosures in the accompanying notes, including stock-based compensation expense, accrued expenses (including accrued expenses related to research and development (“R&D”) as described below), and the recoverability of the Company’s net deferred tax assets and related valuation allowance. The Company bases its estimates, assumptions and judgments on historical experience when available and on various factors that it believes to be reasonable under the circumstances as of the date of the accompanying consolidated financial statements. In addition, other factors may affect estimates, including the expected business and operational changes, the sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ materially from the estimates and assumptions used in the preparation of the accompanying consolidated financial statements under different assumptions or conditions. 7 Accrued Expenses Related to R&D Expenses As part of the process of preparing our consolidated financial statements, we are required to estimate our R&D expenses as of each balance sheet date. This process involves reviewing open contracts, including clinical site contracts, and communicating with our personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our R&D expenses as of each balance sheet date based on facts and circumstances known to us at that time. The significant estimates in our R&D expenses include the costs incurred for services performed by our vendors in connection with services for which we have not yet been invoiced. We base our expenses related to R&D activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with contractors and vendors that conduct R&D on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. Advance payments for goods and services that will be used in future R&D activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred. Segment Reporting and Geographic Concentrations The Company manages its operations as a single operating segment in the U.S. (see Note 10). Fair Value of Financial Instruments Authoritative guidance requires disclosure of the fair value of financial instruments. The Company applies fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities, approximate their estimated fair values primarily due to the short-term nature of the instruments or based on information obtained from market sources and management estimates. The Company measures the fair value of certain of its financial liabilities on a recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value, which is not equivalent to cost, will be classified and disclosed in one of the following three categories: · Level 1 — Quoted prices (unadjusted) in active markets for identical assets and liabilities; · Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and · Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. The Company reviews the fair value hierarchy classification at each reporting date. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the years presented. As of June 30, 2026 and December 31, 2025, there were no financial assets or liabilities carried at fair value which were not equivalent to cost. 8 Comprehensive Loss There were no differences between net loss and comprehensive loss presented in the unaudited condensed consolidated statements of operations for the three and six months ended June 30, 2026 and 2025. Net Loss Per Share Attributable to Common Stockholders Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, unvested RSAs, outstanding stock options and RSUs are considered to be potentially dilutive securities when outstanding (see Note 9). Because the Company has reported a net loss for the reporting periods presented, the diluted net loss per common share is the same as basic net loss per common share for those periods. Recently Issued Accounting Standards Not Yet Adopted Accounting standards not listed below were assessed and determined not to be applicable or are expected to have minimal impact on the Company’s unaudited condensed consolidated financial statements. In November 2024, the FASB issued ASU 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses”. This amended guidance requires disaggregation of specific expense categories in the notes to the financial statements and a qualitative description of the remaining expense amounts not separately disaggregated. This standard becomes effective for reporting companies with annual reporting periods beginning after December 15, 2026, and requires prospective application with an option to apply it retrospectively. The Company anticipates adopting this standard in its Annual Report on Form 10-K for the year ending December 31, 2027. The Company is currently evaluating the impact that the adoption of this standard will have on its consolidated financial statements. 3. OTHER ACCRUED EXPENSES Other accrued expenses as of June 30, 2026 and December 31, 2025 consisted of the following: Schedule of other accrued expenses June 30, 2026 December 31, 2025 Accrued clinical study costs $ 1,939,501 $ 3,169,433 Other accrued expenses 365,120 397,971 Total other accrued expenses $ 2,304,621 $ 3,567,404 4. COMMITMENTS AND CONTINGENCIES Operating Lease On December 1, 2024, the Company rented office space on a month-to-month basis with no long-term commitment, representing a short-term lease. As a result, the Company has elected to apply the short-term lease exemption to its office lease and therefore has not recorded a right of use (“ROU”) asset and related lease liability in accordance with ASC 842, Leases (“ASC 842”). Rent expense recorded during the three and six months ended June 30, 2026 was $ 13,100 and $ 26,000 , respectively, which amounts are included in general and administrative expenses in the accompanying unaudited condensed consolidated statement of operations. For the three and six months ended June 30, 2025, rent expense was $ 12,800 and $ 25,400 , respectively. 9 Legal The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes and are not predictable with certainty. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business in which the Company is or could become involved in litigation may have a material adverse effect on its business and financial condition. To the Company’s knowledge, the Company is not subject to any ongoing or pending legal proceedings. Indemnities and Guarantees We have made certain indemnities and guarantees, under which we may be required to make payments to a guaranteed or indemnified party, in relation to certain transactions. We indemnify our officers and directors to the maximum extent permitted under the laws of the State of Delaware. The duration of these indemnities and guarantees varies and, in certain cases, is indefinite. These indemnities and guarantees do not provide for any limitation of the maximum potential future payments we could be obligated to make. Historically, we have not been obligated to make any payments for these obligations and no liabilities have been recorded for these indemnities and guarantees in the accompanying unaudited condensed consolidated balance sheets. 5. LICENSES AND AGREEMENTS UIC License Agreement On April 6, 2015, the Company entered into an Exclusive License Agreement with Equity (the “UIC License Agreement”) with The Board of Trustees of the University of Illinois (“UIC”), whereby, UIC granted the Company (a) an exclusive, non-transferable license, with the right to sublicense under UIC’s rights in the Patent Rights (as defined in the UIC License Agreement), and (b) a non-exclusive, non-transferable worldwide license, with the right to sublicense, to use UIC’s rights in the Technical Information (as defined in the UIC License Agreement) for all uses. In consideration of the license granted under the UIC License Agreement, the Company agreed to pay UIC (i) development milestones of up to $1.25 million, of which, up to $0.25 million is due upon the progress of clinical studies and $1.0 million is due upon the initiation of commercial sales, (ii) annual minimum royalty payments, increasing to $50,000 in year six and each year thereafter, (iii) royalty on net sales for product covered under the Patent Rights in the low single digits with a 50% reduction in royalties for products solely utilizing Technical Information, (iv) a declining percentage of sublicensing revenue based on the escalating stage of development upon a sublicensing event, and (v) the reimbursement of all patent and related expenses incurred by UIC covering the Patent Rights. For the three and six months ended June 30, 2026, the Company incurred minimum royalty expenses to UIC in the aggregate amount of $ 50,000 and $ 56,851 , respectively, which amounts were included in general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations. For the three and six months ended June 30, 2025, the Company incurred minimum royalty expenses and other reimbursable expenses to UIC in the aggregate amount of $ 50,055 and $ 58,158 , respectively, which amounts were included in general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations. In addition, the Company entered into a sublicense and collaboration agreement dated August 28, 2017 with an unrelated entity that was covered under the UIC License Agreement, which sublicense agreement was later terminated on January 31, 2018. Under the UIC License Agreement, the Company owed UIC a certain percentage of amounts received under the sublicense agreement in the amount of $ 449,990 . The Company paid UIC 10% of the sublicense fees in the amount of $ 44,999 and the remaining unpaid balance of $ 404,991 (“Deferred Amount”) was originally due and payable to UIC in two installments: 50% due and payable on the one-year anniversary from the first commercial sale and 50% due on the second-year anniversary from the first commercial sale. The Deferred Amount is treated as debt and continues to accrue interest at a rate of five percent (5%) per annum, representing the prime rate as of the date of the agreement plus 1%. On July 16, 2024, the Company and UIC entered into an amendment to the UIC License Agreement (“UIC Amendment”). Interest is due and payable annually within 30 days following the second anniversary of the closing of the IPO and annually thereafter. In addition, the UIC Amendment provides for payment of the Deferred Amount and any accrued interest thereon upon the sooner of (i) termination of the UIC License Agreement by the Company, (ii) the Company ceases development of the licensed UIC technology, (iii) the Company consummates a Change in Control (as defined in the UIC License Agreement), (iv) the Company sublicenses the licensed technology or the developed product, (v) the one-year anniversary following approval of a NDA of a licensed product, or (vi) the Company executes a partnership agreement with any entity resulting in the payment to us above a specified milestone amount or the Company secures cumulative financing equal to or exceeding $200 million. In addition, the UIC Amendment provides that to the extent the Company secures equity financing equal to or exceeding $85 million through its IPO or otherwise, 50% of the Deferred Amount is due and payable within 30 days. The remaining 50% of the Deferred Amount shall be due and payable upon the first to occur of any of the events noted above in clauses (i) through (vi). Finally, the UIC Amendment provides that for as long as the Company or a sublicensee is selling the licensed product, the Company will pay all consideration provided for in the original UIC License Agreement and described above until the last to expire market exclusivity date, the period of which for all products in a jurisdiction will not exceed a total of seven (7) years beginning with the date regulatory approval is granted for the first licensed product in the jurisdiction, and such obligation will survive termination of the UIC License Agreement. 10 As of June 30, 2026 and December 31, 2025, interest payable to UIC was $ 37,143 and $ 27,018 , respectively, included in the accompanying unaudited condensed consolidated balance sheets. 6. STOCKHOLDERS’ EQUITY Authorized and Issued Capital The Company’s authorized capital consists of 200,000,000 shares of common stock, $ 0.000001 par value per share, and 10,000,000 shares of preferred stock, $ 0.000001 par value per share. As of June 30, 2026 and December 31, 2025, there were 24,013,577 and 23,245,203 shares of common stock issued and outstanding, respectively. There were no shares of preferred stock outstanding as of June 30, 2026 or December 31, 2025. Funding Agreements November 2025 ATM Facility During the six months ended June 30, 2026, the Company sold 498,193 shares of common stock at a weighted-average price of $2.66 per share for net proceeds of $ 1,249,591 , before the amortization of deferred offering costs of $ 1,622 , under the ATM Facility. As of June 30, 2026, the Company had approximately $ 98.7 million in remaining capacity under its ATM Facility (see Note 1). Committed Equity Facility On March 27, 2025, the Company entered into a Committed Equity Facility with B. Riley giving the Company the right, but not the obligation, to sell to B. Riley over a 36-month period up to the lesser of (i) $50 million of newly issued shares of our common stock and (ii) 3,904,374 shares of the Company’s common stock. The price per share of common stock sold to B. Riley is determined by reference to the daily volume-weighted average price of the Company’s common stock as defined within the Committed Equity Facility less a 3% discount, subject to certain limitations and conditions, as calculated on each day the Company sells shares of its common stock under the Committed Equity Facility. The total net proceeds that the Company will receive under the Committed Equity Facility will depend on the quantity, frequency and prices at which the Company sells common stock to B. Riley. During the six months ended June 30, 2026, there were no sales to B. Riley under the Committed Equity Facility. Issuance of Common Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for share-based stock awards based on estimated fair values equaling either the market value of the shares issued, or the value of consideration received, whichever is more readily determinable. The Company did no t issue any shares of restricted common stock during the three months ended June 30, 2026. During the three months ended March 31, 2026, the Company issued 50,000 shares of restricted common stock that immediately vested in exchange for services provided to the Company and recorded a non-cash expense of $ 138,500 based on the fair market value of the restricted stock award on the issuance date, which amount was included in general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations. Reserved Shares As of June 30, 2026, the Company reserved the following shares of common stock for issuance upon the (i) exercise of outstanding warrants, (ii) issuance of shares reserved under the Committed Equity Facility, (iii) exercise of issued and outstanding stock option awards and restricted stock unit awards, and (iv) to reserve the remaining shares available for grant under the 2024 Stock Incentive Plan (“2024 Plan”): Schedule of reserved shares of common stock for issuance June 30, 2026 Shares of common stock reserved under the Committed Equity Facility 3,364,407 Shares reserved for issuance under the 2024 Plan 2,432,742 Stock option awards issued and outstanding 2,755,836 Warrants issued and outstanding to purchase common stock 922,096 Restricted stock unit awards issued and outstanding 275,181 Total 9,750,262 The number of shares of common stock reserved for issuance above excludes shares available for issuance under the ATM Facility. 11 7. WARRANTS As of June 30, 2026, the following warrants to purchase shares of common stock were outstanding: Schedule of warrant outstanding Warrants Outstanding Exercise Price per Share Expiry Date June 2025 Private Placement Warrants 666,497 $ 7.00 Warrant Expiry Date (defined below) Underwriter warrants issued under IPO 161,000 $ 10.00 August 12, 2027 Warrants originally issued in conjunction with Series B Redeemable Convertible Preferred Stock 76,376 $ 10.55 August 13, 2026 Warrants originally issued in conjunction with Series C Redeemable Convertible Preferred Stock 18,223 $ 9.42 August 13, 2026 Total 922,096 June 2025 Private Placement Warrant On June 25, 2025, the Company entered into a securities purchase agreement for a private placement of common stock and warrants with certain institutional and accredited investors, including Bios 2024 Co-Invest, LP. Dr. Aaron G.L. Fletcher, the Chairman of the Company’s Board of Directors, is a Managing Partner and co-founder of Bios Partners, of which Bios 2024 Co-Invest, LP is an affiliate entity. Upon closing of the private placement on June 27, 2025, the Company issued warrants to purchase up to an aggregate of 666,497 shares of common stock at an exercise price of $ 7.00 per share. The warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (“FDA”) issuing Breakthrough Therapy Designation (“BTD”) for elraglusib and (ii) the date that the FDA provides written communication available to the Company of its determination as to whether the Company may pursue registration for elraglusib using its currently available Phase 2 data or data from a future Phase 3 clinical study (“Warrant Expiry Date”). 8. EQUITY COMPENSATION PLANS Stock Incentive Plans Our board of directors adopted and our stockholders approved our 2024 Plan, which became effective on August 12, 2024. The purpose of the 2024 Plan is to enhance the Company’s ability to attract, retain and motivate individuals by providing these individuals with equity ownership and incentive opportunities. All of the Company’s employees, as well as all of the Company’s non-employee directors and other consultants, advisors and other persons who provide services to the Company are eligible to receive incentive awards under the 2024 Plan, including stock options grants, stock appreciation rights (“SARs”), restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and other awards. Up to 3,316,444 shares of common stock were originally reserved for future issuance under the 2024 Plan, which number included 496,801 shares of common stock reserved for issuance under the 2015 Plan as of the closing date of the IPO. In addition, the number of shares of common stock available for issuance under the 2024 Plan is subject to an annual increase on the first day of each calendar year beginning on January 1, 2025 and ending on and including January 1, 2034 equal to the lesser of (i) 5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares of common stock as determined by the Board. Effective January 1, 2026, the number of shares of common stock reserved for issuance under the 2024 Plan increased by 1,162,260 pursuant to the aforementioned evergreen provision. As of June 30, 2026, there were 2,432,742 shares available for grant under the 2024 Plan. In addition, the Company had previously adopted the 2015 Stock Incentive Plan (the “2015 Plan”). As of June 30, 2026, there were 347,600 stock options outstanding and 12,568 unvested RSAs outstanding under the 2015 Plan. On August 12, 2024, the effective date of the 2024 Plan, there were no remaining shares available for grant under the 2015 Plan. 12 Restricted Stock Awards There were no RSAs granted during the six months ended June 30, 2026. At June 30, 2026, the total estimated unrecognized compensation cost related to unvested service-based RSAs and unvested performance based RSAs was approximately $ 400 and $ 42,000 , respectively. The unrecognized cost related to service-based RSAs is expected to be recognized over the remaining weighted average vesting period of 0.02 years. The unrecognized cost related to performance-based RSAs will be recognized ratably over the performance period based upon the probable number of shares expected to vest. During the six months ended June 30, 2026 and 2025, there was no expense recorded for the outstanding performance-based RSAs. The following summarizes our RSAs transaction activity for six months ended June 30, 2026: Schedule of RSAs transaction activity Restricted Common Stock Award Shares Weighted Average Grant Date Fair Value ($) Unvested balance at December 31, 2025 17,617 3.10 Granted – – Vested ( 5,049 ) 2.11 Forfeited – – Unvested balance at June 30, 2026 12,568 3.50 Restricted Stock Units At June 30, 2026, the total estimated unrecognized compensation cost related to unvested RSUs was approximately $ 321,000 . This cost is expected to be recognized over the remaining weighted average vesting period of 0.13 years. The following summarizes our RSUs transaction activity for the six months ended June 30, 2026: Schedule of RSUs transaction activity Restricted Common Stock Unit Shares Weighted Average Grant Date Fair Value ($) Outstanding at December 31, 2025 617,236 9.13 Granted – – Vested and settled ( 342,055 ) 9.14 Forfeited – – Outstanding at June 30, 2026 275,181 9.13 Unvested at June 30, 2026 275,181 9.13 During the six months ended June 30, 2026, the Company withheld 121,874 shares of common stock related to the net settlement of certain RSUs that settled during the period to cover the withholding of taxes in the amount of $ 527,716 . Stock Options The following summarizes our stock option transaction activity for the six months ended June 30, 2026: Schedule of stock option transaction activity Number of Stock Options Grant Date Weighted Average Exercise Price ($) Outstanding at December 31, 2025 1,841,977 6.51 Options granted 950,000 2.48 Options exercised – – Options canceled and forfeited ( 36,141 ) 4.85 Outstanding at June 30, 2026 2,755,836 5.14 13 As of June 30, 2026, total unrecognized stock-based compensation cost related to stock options was approximately $ 5,940,000 . This cost is expected to be recognized over the weighted average remaining period of 1.42 years. The following table provides the assumptions used in determining the estimated fair value of stock option awards granted during the six months ended June 30, 2026: Schedule of assumptions Expected volatility 99.95 % Risk-free interest rate 4.03 % Expected dividend yield 0.00 % Expected term (in years) 6.01 The following table summarizes the stock-based compensation expense recorded in the accompanying unaudited condensed consolidated statements of operations during the three and six months ended June 30, 2026 and 2025: Schedule of stock-based compensation expense Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Research and development $ 195,048 $ 88,363 $ 351,718 $ 217,289 General and administrative 1,145,721 1,490,908 2,345,440 2,487,083 Total $ 1,340,769 $ 1,579,271 $ 2,697,158 $ 2,704,372 The Company has not recognized and does not expect to recognize in the near future, any tax benefit related to employee stock-based compensation expense as a result of the full valuation allowance related to its net deferred tax assets. 9. Net Loss Per Share Attributable to Common Stockholders The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders during the three and six months ended June 30, 2026 and 2025: Schedule of computation of basic and diluted net loss per share attributable to common stockholders Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Numerator: Net loss $ ( 4,866,635 ) $ ( 5,949,405 ) $ ( 10,492,384 ) $ ( 12,266,429 ) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 23,871,850 19,646,475 23,705,417 19,572,564 Net loss per share attributable to common stockholders, basic and diluted $ ( 0.20 ) $ ( 0.30 ) $ ( 0.44 ) $ ( 0.63 ) The potential dilutive effect of outstanding stock options, unvested RSAs, unvested RSUs, and outstanding warrants during the period are calculated in accordance with the treasury stock method, but are excluded if their effect is anti-dilutive. The number of whole shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect were as follows: Schedule of anti-dilutive shares June 30, 2026 2025 Options issued and outstanding 2,755,836 1,774,477 Warrants issued and outstanding 922,096 922,096 Unvested RSUs 275,181 584,111 Unvested RSAs 12,568 22,667 Total 3,965,681 3,303,351 14 10. SEGMENT REPORTING The Company manages its operations as a single operating segment, which includes all activities related to the development and potential commercialization of novel therapies for the treatment of cancer, for the purposes of assessing performance and making operating decisions. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company’s chief operating decision maker (“CODM”). The Company’s CODM is its President and Chief Executive Officer, who reviews and evaluates consolidated net income (loss) for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods. In addition to the significant expense categories included within consolidated net income (loss) presented on the Company’s unaudited condensed consolidated statements of operations, see below for disaggregated amounts that comprise research and development expenses for the three and six months ended June 30, 2026 and 2025: Schedule of research and development expenses Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Personnel and consulting expenses $ 1,031,747 $ 858,546 $ 2,240,958 $ 1,715,239 External clinical study expenses 772,019 1,521,617 1,353,208 3,355,988 Nonclinical and biomarker research 197,323 250,811 735,400 343,212 Chemistry Manufacturing & Control (“CMC”) related costs 65,736 133,831 302,503 570,685 Total research and development expenses $ 2,066,825 $ 2,764,805 $ 4,632,069 $ 5,985,124 In addition, the Company has a wholly-owned subsidiary, Actuate Therapeutics Limited, which is a dormant entity with no assets, liabilities or operations in any foreign countries. 11. SUBSEQUENT EVENTS The Company has evaluated all subsequent events and transactions through the date these unaudited condensed consolidated financial statements were issued, to ensure these financial statements include appropriate disclosure of events both recognized in the financial statements and events which occurred but were not recognized in the financial statements. The Company has concluded that no subsequent event has occurred that requires disclosure. 15 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis of the financial condition and results of our operations should be read together with the financial statements and related notes of Actuate Therapeutics, Inc. included in Part I Item 1 of this Quarterly Report on Form 10-Q (“Quarterly Report” or “Report”) and with our audited consolidated financial statements and the related notes thereto for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 26, 2026. This discussion and analysis contains forward-looking statements reflecting our management’s current expectations that involve risks, uncertainties, and assumptions. See the section entitled “Cautionary Note Regarding Forward-Looking Statements.” Our actual results and the timing of events may differ materially from those described in or implied by these forward-looking statements due to a number of factors, including those discussed below and elsewhere in this Report, particularly those set forth under “Risk Factors.” Business Overview We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (“GSK-3”). We are developing elraglusib, an ATP-competitive small molecule that is designed to enter cancer cells and block the function of the enzyme glycogen synthase kinase-3 beta (“GSK-3β”), a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. We believe that the blockade of GSK-3β signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. There are no approved high-affinity inhibitors of GSK-3β, and we believe elraglusib is one of the most advanced GSK-3β inhibitors in clinical development. We have exclusively licensed elraglusib, a proprietary and patent protected GSK-3 inhibitor developed through a collaboration between The Board of Trustees of the University of Illinois-Chicago (“UIC”) and Northwestern University (“NU”). We believe elraglusib represents a “pipeline in a molecule” with a broad opportunity for us to potentially initiate and advance multiple drug development programs around our lead asset based on its multimodal mechanisms of action, data emerging from completed or ongoing clinical studies and nonclinical biological, cellular, and animal data. Animal tumor model data, clinical study data and AI-based computational approaches have identified a number of areas of unmet clinical need in cancer treatment where elraglusib may play an interventional role, including pancreatic, metastatic melanoma, lung, colon, breast, renal, and ovarian cancer, leukemias and lymphomas, as well as some pediatric cancers including Ewing sarcoma, neuroblastoma and pediatric leukemias. To date, we have treated over 500 patients with elraglusib as an IV injection (“Elraglusib Injection”) in Phase 1 and Phase 2 studies. We have also developed an oral formulation of elraglusib (“Elraglusib Oral Tablet”), which we believe will allow us to pursue a number of cancer indications with a more convenient dose delivery option for patients with the ability to dose patients on a daily basis. We filed an Investigational New Drug (“IND”) application with the FDA in April 2026 to advance the Elraglusib Oral Tablet into a Phase 1/2 clinical study to identify the maximum tolerated dose and Recommended Phase 2 Dose (“RP2D”) in adult patients with advanced, refractory cancers, and we recently received FDA clearance to proceed with the Phase 1/2 clinical study. Once we have determined a RP2D, several Phase 2 or registrational studies have been identified for further clinical development of Elraglusib Oral Tablet, subject to additional funding, based on data from previous studies, including but not limited to, first-line metastatic pancreatic ductal adenocarcinoma (“mPDAC”), refractory, metastatic melanoma, refractory, metastatic colorectal cancer, and non-small cell lung cancer. In addition, we have generated promising results with a once weekly IV infusion of elraglusib in first-line treatment of patients with mPDAC. Our Phase 2 clinical study in mPDAC, known as Actuate-1801 Part 3B, is a randomized, controlled Phase 2 clinical study that enrolled 286 patients with no prior systemic treatment for metastatic disease. The primary endpoint for this clinical study was median overall survival (“mOS”), with overall survival (“OS”) summarized throughout the study by estimates of 1-year survival. Updated data results presented at the American Society of Clinical Oncology (“ASCO”) Gastrointestinal Cancers Symposium (“ASCO GI”) in January 2026, utilizing a data cutoff as of November 22, 2025, showed that the clinical study met its primary endpoint, demonstrating a statistically significant improvement in mOS with elraglusib plus gemcitabine/nab-paclitaxel (“GnP”) versus GnP alone. Data presented at ASCO GI included: · Statistically significant benefit in mOS in the elraglusib/GnP arm vs GnP control arm (mOS 10.1 months vs. 7.2 months, p=0.02, HR=0.62); · Near doubling of the 12-month survival rate, from 22.3% in the GnP arm to 44.4% in the elraglusib/GnP arm; and · Almost fivefold increase in 24-month survival rate, from 2.6% in the GnP control arm to 12.9% in the elraglusib/GnP arm, emphasizing the potential for long-term clinical benefit. 16 While these data are impressive with once weekly dosing, we believe we can further improve the outcome of patients using the Elraglusib Oral Tablet at the RP2D, including a more frequent dosing regimen to be identified in the Phase 1/2 clinical study. We believe this strategy will further align with other new approaches to treating mPDAC with investigational products that are delivered orally to patients. In addition, the safety profile of elraglusib in over 500 patients to date shows the product is well tolerated as a monotherapy and in combination with chemotherapy. We believe this may allow the Elraglusib Oral Tablet to be combined with other investigational products, including but not limited to RAS and MEK inhibitors, where possible additive or synergistic mechanisms of action may potentiate better outcomes for patients treated with combination therapy including elraglusib. In addition to our development plans for the Elraglusib Oral Tablet, we have advanced the development of Elraglusib Injection in pediatric cancer patients with recurrent/refractory solid cancers. This clinical study, Actuate-1902, is a Phase 1/2 study that evaluated escalating doses of elraglusib as a single agent as well as in combination with irinotecan or cyclophosphamide/topotecan in the Phase 1 portion of the study. Patients in the Actuate-1902 study also experienced a number of objective responses in the combination chemotherapy arms, and based on these data, we identified neuroblastoma and Ewing sarcoma as possible new indications for further development of Elraglusib Injection, pending additional funding primarily focused on non-dilutive sources of capital, further expanding the potential use and positive therapeutic impact of elraglusib. In June 2026, we entered into an initial agreement with the University of Birmingham to evaluate elraglusib in the BEACON2 clinical study, an international, multi-arm, multi-stage platform clinical study designed to identify and advance promising treatment approaches for children with relapsed and refractory neuroblastoma. The planned clinical study is expected to enroll up to 20 patients with relapsed and refractory neuroblastoma in a dose confirmation cohort to evaluate safety and to determine the maximum tolerated dose (“MTD”), RP2D, and pharmacokinetics (“PK”) profile of the combination of elraglusib with dinutuximab beta plus chemotherapy. Following completion of the dose confirmation stage, the regimen may advance into a randomized portion of the study, where approximately 75 patients will be enrolled with a planned interim analysis. Components of Our Results of Operations Our operating expenses consist of (i) research and development expenses and (ii) general and administrative expenses. Research and Development Expenses Research and development expenses consist primarily of external and internal costs incurred in performing clinical and nonclinical development activities. Our external research and development costs primarily consist of the costs incurred under agreements with hospitals that treat and monitor patients enrolled in our clinical studies, contract research organizations and contract manufacturers, consultants, and other third parties that conduct and support our clinical studies and nonclinical studies. Our internal research and development costs primarily include research and development personnel-related expenses such as employee compensation, benefits, employer taxes, insurance, and stock-based compensation. We expense research and development costs as incurred. We currently have only one product candidate, elraglusib. Therefore, since our inception, substantially all of our research and development costs were related to the development of elraglusib. We track research and development expenses on an aggregate basis and not on an indication-by-indication or treatment setting-by-treatment setting basis. Although research and development activities are central to our business model, the successful development of elraglusib and any future product candidates is highly uncertain. There are numerous factors associated with the successful development of any product candidate such as elraglusib, including future study design and various regulatory requirements, many of which cannot be determined with accuracy at this time given our stage of development. In addition, future regulatory factors beyond our control may impact our clinical development programs. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased number of patients and longer duration of later-stage clinical studies. As a result, we expect our research and development expenses to increase substantially in connection with our ongoing and planned clinical and nonclinical development activities in the near term and in the future, provided we are able to raise additional capital. At this time, we cannot accurately estimate or know the nature, timing, and costs of the efforts that will be necessary to complete the nonclinical and clinical development of elraglusib and any future product candidates. Our future research and development expenses may vary significantly based on a wide variety of factors such as: 17 · the results of our clinical studies and nonclinical studies of elraglusib and any future product candidates we may choose to pursue, including any modifications to clinical development plans based on feedback that we may receive from regulatory authorities; · per patient clinical study costs; · the number of clinical studies required for approval; · the number of sites included in the clinical studies and the number of countries in which the studies are conducted; · the number of patients who participate in the clinical studies, the drop-out or discontinuation rates of patients, and the length of time required to enroll eligible patients; · the number of doses that patients receive; · the potential additional safety monitoring requested by regulatory agencies; · the duration of patient participation in the clinical studies and follow-up; · the cost and timing of manufacturing elraglusib and any future product candidates; · the costs, if any, of obtaining third-party drugs for use in our combination clinical studies; · the extent of changes in government regulation and regulatory guidance; · the efficacy and safety profile of elraglusib and any future product candidates; · the timing, receipt, and terms of any approvals from applicable regulatory authorities; and · the extent to which we establish additional collaboration, license, or other arrangements. A change in the outcome of any of these variables with respect to the development of elraglusib or any future product candidates could significantly change the costs and timing associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any product candidate. General and Administrative Expenses General and administrative expenses consist primarily of personnel-related expenses, such as employee compensation, benefits, and stock-based compensation, for our personnel in executive and other administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters and professional fees paid for accounting, auditing, consulting, and tax services, as well as other costs such as insurance costs, board of director fees, investor and public relations, and travel expenses. We anticipate our general and administrative expenses will increase in the future as we expand our operations, including increasing our headcount to support our continued research and development activities and preparing for later-stage clinical studies and potential commercialization of elraglusib. We also anticipate we will continue to incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance, and investor and public relations expenses associated with operating as a public company. Other Income (Expense) Interest Expense Interest expense represents interest owed to UIC under our license agreement with UIC, whereby UIC agreed to defer amounts owed to UIC under a former sublicense agreement in the amount of $404,991. Interest Income Interest income represents interest earned on our cash and cash equivalents at the then-prevailing market rates. 18 Results of Operations We have incurred significant operating losses and negative cash flows from operations since our inception. Our net losses were $22,227,852 and $27,285,328 for the years ended December 31, 2025 and 2024, respectively, and $10,492,384 and $12,266,429 for the six months ended June 30, 2026 and 2025, respectively. As of June 30, 2026, we had an accumulated deficit of $165,100,085. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and general and administrative costs associated with our operations. We expect to continue to incur significant expenses and operating losses for the foreseeable future, and we anticipate these losses will increase substantially as we continue our development of, seek regulatory approval for, and potentially commercialize elraglusib, and potentially seek to discover, acquire and develop additional product candidates, utilize third parties to manufacture elraglusib, hire additional personnel, expand and protect our intellectual property, and incur additional costs associated with operating as a public company. If we obtain regulatory approval for elraglusib, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, and distribution. Comparison of the Three Months Ended June 30, 2026 and 2025: The following table summarizes our results of operations for the three months ended June 30, 2026 and 2025: Three Months Ended June 30, 2026 2025 Change Operating expenses: Research and development $ 2,066,825 $ 2,764,805 $ (697,980 ) General and administrative 2,839,763 3,204,072 (364,309 ) Total operating expenses 4,906,588 5,968,877 (1,062,289 ) Loss from operations (4,906,588 ) (5,968,877 ) 1,062,289 Other income (expense): Interest expense (5,063 ) (5,062 ) (1 ) Interest income 45,016 24,534 20,482 Total other income, net 39,953 19,472 20,481 Net loss $ (4,866,635 ) $ (5,949,405 ) $ 1,082,770 Research and Development Expenses The following table summarizes our research and development expenses for the three months ended June 30, 2026 and 2025: Three Months Ended June 30, 2026 2025 Change External clinical study expenses $ 772,019 $ 1,521,617 $ (749,598 ) CMC related costs 65,736 133,831 (68,095 ) Nonclinical and biomarker research 197,323 250,811 (53,488 ) Personnel and consulting expenses 1,031,747 858,546 173,201 Total research and development expenses $ 2,066,825 $ 2,764,805 $ (697,980 ) The decrease in research and development expenses of $697,980 for the three months ended June 30, 2026 compared to the same prior year period was primarily due to (i) a decrease in external clinical study expenses of $749,598 mostly related to lower patient fees and CRO costs associated with fewer patients on study during the current period related to the randomized Phase 2 mPDAC clinical study (Actuate-1801 Part 3B), (ii) a decrease of $68,095 in CMC related costs primarily due to the timing of our stability studies, and (iii) a decrease of $53,488 in nonclinical and biomarker research costs primarily related to lower bioanalytical costs. These decreases were partially offset by an increase in personnel and consulting expenses of $173,201 primarily due to an increase in non-cash stock-based compensation expense of $106,685 related to awards granted to employees and consultants of the Company. 19 General and Administrative Expenses The following table summarizes our general and administrative expenses for the three months ended June 30, 2026 and 2025: Three Months Ended June 30, 2026 2025 Change Personnel-related expenses $ 1,605,221 $ 2,120,096 $ (514,875 ) Other expenses 399,225 467,851 (68,626 ) Professional and consulting fees 835,317 616,125 219,192 Total general and administrative expenses $ 2,839,763 $ 3,204,072 $ (364,309 ) The decrease in general and administrative expenses of $364,309 for the three months ended June 30, 2026 compared to the same prior year period was primarily due to (i) a decrease in personnel-related expenses of $514,875 mostly due to a decrease in non-cash stock-based compensation expense of $345,187 resulting from the timing of amortization of awards granted to employees, non-employee members of the board of directors, and consultants of the Company and (ii) a decrease in other expenses of $68,626 primarily related to lower insurance costs and travel costs. These decreases were partially offset by a current period increase in professional and consulting fees of $219,192 mostly due to an increase in investor and public relations fees. Other Income (Expense) Other income (expense), net, for the three months ended June 30, 2026 and 2025 was comprised of the following: · Interest expense — Interest expense for the three months ended June 30, 2026 and 2025 represents interest accrued on amounts owed under a license agreement with UIC, whereby UIC agreed to defer amounts payable to UIC under a former sublicense agreement in the amount of $404,991 in exchange for an interest-bearing license payable. · Interest income — Interest income for the three months ended June 30, 2026 and 2025 represents interest earned on cash and cash equivalents based on the then-prevailing market rates. The increase in interest income for the three months ended June 30, 2026 compared to the same prior year period was primarily due to a higher average cash balance on hand compared to the same prior year period. Comparison of the Six Months Ended June 30, 2026 and 2025: The following table summarizes our results of operations for the six months ended June 30, 2026 and 2025: Six Months Ended June 30, 2026 2025 Change Operating expenses: Research and development $ 4,632,069 $ 5,985,124 $ (1,353,055 ) General and administrative 5,980,475 6,349,337 (368,862 ) Total operating expenses 10,612,544 12,334,461 (1,721,917 ) Loss from operations (10,612,544 ) (12,334,461 ) 1,721,917 Other income (expense): Interest expense (10,125 ) (10,125 ) – Interest income 130,285 78,157 52,128 Total other income (expense), net 120,160 68,032 52,128 Net loss $ (10,492,384 ) $ (12,266,429 ) $ 1,774,045 20 Research and Development Expenses The following table summarizes our research and development expenses for the six months ended June 30, 2026 and 2025: Six Months Ended June 30, 2026 2025 Change External clinical study expenses $ 1,353,208 $ 3,355,988 $ (2,002,780 ) CMC related costs 302,503 570,685 (268,182 ) Personnel and consulting expenses 2,240,958 1,715,239 525,719 Nonclinical and biomarker research 735,400 343,212 392,188 Total research and development expenses $ 4,632,069 $ 5,985,124 $ (1,353,055 ) The decrease in research and development expenses of $1,353,055 for the six months ended June 30, 2026 compared to the same prior year period was primarily due to a decrease in external clinical study expenses of $2,002,780 mostly related to lower patient fees and CRO costs associated with fewer patients on study during the current period related to the randomized Phase 2 mPDAC clinical study (Actuate-1801 Part 3B) combined with a decrease in CMC related costs of $268,182 in the current period primarily due to the timing of drug product manufacturing and stability studies to support ongoing and planned clinical studies. These decreases in expenses in the current period were partially offset by (i) an increase in personnel and consulting expenses of $525,719 primarily due to increased headcount, an increase in medical and regulatory consulting associated with ongoing regulatory filings, and an increase in non-cash stock-based compensation expense of $134,429 and (ii) an increase in nonclinical and biomarker research studies in the amount of $392,188 due to greater nonclinical studies and bioanalytical studies conducted in the current period to support advancing elraglusib and the oral tablet formulation. General and Administrative Expenses The following table summarizes our general and administrative expenses for the six months ended June 30, 2026 and 2025: Six Months Ended June 30, 2026 2025 Change Personnel-related expenses $ 3,399,878 $ 3,747,427 $ (347,549 ) Other expenses 774,512 847,100 (72,588 ) Professional and consulting fees 1,806,085 1,754,810 51,275 Total general and administrative expenses $ 5,980,475 $ 6,349,337 $ (368,862 ) The decrease in general and administrative expenses of $368,862 for the six months ended June 30, 2026 compared to the same prior year period was primarily due to (i) a decrease in personnel-related expenses of $347,549 related to lower amounts accrued for annual bonuses in the current period combined with lower non-cash stock-based compensation expense of $141,643 related to the timing of amortization of awards granted to employees, non-employee members of the board of directors, and consultants of the Company and (ii) a decrease in other expenses of $72,588 primarily related to lower insurance costs and travel costs in the current period. These amounts were partially offset by a current period increase in professional and consulting fees of $51,275, mostly due to an increase in investor and public relations fees. 21 Other Income (Expense) Other income (expense), net, for the six months ended June 30, 2026 and 2025 was comprised of the following: · Interest expense — Interest expense for the six months ended June 30, 2026 and 2025 represents interest accrued on amounts owed under a license agreement with UIC, whereby UIC agreed to defer amounts payable to UIC under a former sublicense agreement in the amount of $404,991 in exchange for an interest-bearing license payable. · Interest income — Interest income for the six months ended June 30, 2026 and 2025 represents interest earned on cash and cash equivalents based on the then-prevailing market rates. The increase in interest income for the six months ended June 30, 2026 compared to the same prior year period was primarily due to a higher average cash balance on hand compared to the same prior year period. Liquidity and Capital Resources Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from operations. We expect to incur significant expenses and operating losses in the foreseeable future as we advance the clinical development of elraglusib and any future product candidates. On November 28, 2025, the Company entered into an At Market Issuance Sales Agreement (the “ATM Agreement”) with B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC (each a “Sales Agent” and collectively the “Sales Agents”) with respect to an “at the market” offering program (the “ATM Facility”), under which the Company may, from time to time, at its sole discretion, issue and sell through the Sales Agents, up to $100 million of shares of common stock. Pursuant to the ATM Agreement, the Company may sell the shares through the Sales Agents by any method permitted that is deemed an “at the market” offering as defined in Rule 415 under the Securities Act. The Sales Agents will use commercially reasonable efforts consistent with their normal trading and sales practices to sell the shares from time to time, based upon instructions from us, including any price or size limits or other customary parameters or conditions we may impose. The Company will pay the Sales Agents a commission of up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the ATM Agreement and also has provided the Sales Agents with customary indemnification rights. During the six months ended June 30, 2026, the Company sold 498,193 shares of common stock at a weighted-average price of $2.66 per share for net proceeds of $1,249,591 under the ATM Facility. As of June 30, 2026, the Company had approximately $98.7 million in remaining capacity under its ATM Facility. On March 27, 2025, we entered into a common stock purchase agreement (the “Committed Equity Facility”) with B. Riley Principal Capital II (“B. Riley”) giving the Company the right, but not the obligation, to sell to B. Riley over a 36-month period up to the lesser of (i) $50 million of newly issued shares of our common stock and (ii) 3,904,374 shares of the Company’s common stock. During the six months ended June 30, 2026, the Company did not issue any shares of common stock under the Committed Equity Facility. As of June 30, 2026, we had 3,364,407 shares of common stock in remaining capacity under our Committed Equity Facility. As of June 30, 2026, we had cash and cash equivalents of $4,425,841 and working capital of $942,745. We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we continue our development of, seek regulatory approval for, and potentially commercialize elraglusib and potentially seek to discover and develop and/or license or acquire additional product candidates, conduct our ongoing and planned clinical studies and nonclinical studies, continue our research and development activities, utilize third parties to manufacture elraglusib, hire additional personnel, expand and protect our intellectual property, and incur additional costs associated with operating as a public company. Based on our current operating plan, we estimate that our existing cash and cash equivalents as of the date of this Report will not satisfy the Company’s operational and capital requirements beyond September 2026 without raising additional capital. There can be no assurance that the Company will be able to raise sufficient proceeds in the future under the ATM Facility or Committed Equity Facility or any additional financing will be available to the Company on acceptable terms, if at all. 22 Until such time, if ever, that we can generate substantial product revenue, we expect to finance our operations through equity offerings, debt financings, or other capital sources, including current or potential future collaborations, licenses, and other similar arrangements. As we seek additional financing in the near future, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our ability to raise additional funds may be adversely impacted by business conditions, global economic conditions, disruptions to, and volatility in, the credit and financial markets in the United States and worldwide, and diminished liquidity and credit availability. To the extent we raise additional capital through the sale of equity or convertible debt securities, stockholders’ ownership interest in our common stock will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions, engaging in acquisition, merger or collaboration transactions, selling or licensing our assets, making capital expenditures, redeeming our stock, making certain investments or declaring dividends. If we raise additional funds through collaborations or license agreements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity, debt, or other financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves, or even cease operations. Based on the above matters, we have concluded that there is substantial doubt regarding the Company’s ability to continue as a going concern. Material Cash Requirements for Known Contractual and Other Obligations Research and Development Costs We are continuing to invest in our elraglusib clinical studies and have entered into contractual obligations with each clinical study site. Each contract shall continue until the completion of the clinical study at that site. Our clinical study costs are dependent on, among other things, the size, number and duration of each clinical study. Other Capital Requirements and Additional Royalty Obligations. We enter into agreements in the normal course of business with various vendors, which are generally cancellable upon notice. Payments due upon cancellation typically consist only of payments for services provided or expenses incurred, including non-cancellable obligations of service providers, up to the date of cancellation. Cash Flow Summary The following table provides a summary of our cash flows for the six months ended June 30, 2026 and 2025: Six Months Ended June 30, 2026 2025 Net cash used in operating activities $ (9,422,450 ) $ (8,792,501 ) Net cash provided by financing activities 688,868 6,643,535 Net change in cash and cash equivalents $ (8,733,582 ) $ (2,148,966 ) 23 Cash Flows From Operating Activities Six Months Ended June 30, 2026  — Net cash used in operating activities for the six months ended June 30, 2026 consisted of our net loss of $10,492,384 combined with cash used by a net change in operating assets and liabilities of $1,775,849, which amounts were partially offset by (i) non-cash stock-based compensation expense of $2,697,158, (ii) non-cash stock issued for services of $138,500, and (iii) an increase in accrued interest on license payable of $10,125. Six Months Ended June 30, 2025  — Net cash used in operating activities for the six months ended June 30, 2025 consisted of our net loss of $12,266,429, which amount was partially offset by (i) non-cash stock-based compensation expense of $2,704,372, (ii) cash provided by a net change in operating assets and liabilities of $759,431, and (iii) an increase in accrued interest on license payable of $10,125. Cash Flows From Financing Activities Six Months Ended June 30, 2026  — During the six months ended June 30, 2026, net cash provided by financing activities consisted of net proceeds received of $1,251,213 from the sale of shares of common stock under the ATM Facility, before the amortization of deferred offering costs of $1,622, which amount was partially offset by the payment of taxes from withholding of common stock on settlement of restricted stock units of $527,716 and the payment of deferred offering costs of $34,629. Six Months Ended June 30, 2025  — During the six months ended June 30, 2025, net cash provided by financing activities consisted of net proceeds received of (i) $4,621,546 under the June 2025 Private Placement, (ii), $2,163,100 from the sale of common stock to B. Riley under the Committed Equity Facility and (iii) $34,115 from the exercise of stock options, which amounts were partially offset by the payment of deferred offering costs of $175,226. Critical Accounting Estimates Our financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The preparation of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events, and various other factors we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. There were no material changes to our critical accounting estimates as reported in our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 26, 2026. Emerging Growth Company Status and Smaller Reporting Company Status We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). The JOBS Act permits an emerging growth company such as ours to take advantage of an extended transition period to comply with new or revised accounting standards. We have elected to avail ourselves of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we can adopt the new or revised standard at the time private companies adopt the new or revised standard and may do so until such time that we either (i) irrevocably elect to opt out of such extended transition period or (ii) no longer qualify as an emerging growth company. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies. We will continue to remain an emerging growth company until the earliest of the following: (1) the last day of the fiscal year following the fifth anniversary of the date of the completion of the IPO; (2) the last day of the fiscal year in which our total annual gross revenue is equal to or more than $1.235 billion; (3) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (4) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. 24 We are also a smaller reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter. Item 3. Quantitative and Qualitative Disclosures About Market Risk As a “smaller reporting company”, we are not required to provide the information called for by this item. Item 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures As required by Rule 13a-15(b) under the Exchange Act, as of June 30, 2026, the end of the period to which this quarterly report relates, we have carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures. This evaluation was carried out under the supervision and with the participation of our management, including our President and Chief Executive Officer and our Chief Financial Officer. Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including the President and Chief Executive Officer and the Chief Financial Officer as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2026, our management, with the participation of our President and Chief Executive Officer and our Chief Financial Officer, concluded that, as of such date, our disclosure controls and procedures were effective at a reasonable assurance level. Changes in Internal Control Over Financial Reporting. There were no changes in our internal control over financial reporting that occurred during the three months ended June 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 25 PART II- OTHER INFORMATION Item 1A. Risk Factors RISK FACTORS Investing in our common stock involves a high degree of risk. Before you decide to invest in our common stock, you should carefully consider all the information within this Quarterly Report, including the information contained in Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as in our condensed consolidated financial statements and the related notes contained in Part I, Item 1 within this Quarterly Report. In addition, you should carefully consider the risks and uncertainties described in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 26, 2026 (“Annual Report”), our Quarterly Reports on Form 10-Q, as well as in our other public filings with the SEC. If any of the identified risks are realized, our business, results of operations, financial condition, liquidity, and prospects could be materially and adversely affected. In that case, the trading price of our common stock may decline, and you could lose all or part of your investment. In addition, other risks of which we are currently unaware, or which we do not currently view as material, could have a material adverse effect on our business, results of operations, financial condition, and prospects. Other than as set forth below and in Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” there have been no material changes to our risk factors disclosed in Part I, Item 1A, of our Annual Report. We are not currently in compliance with the Nasdaq Global Market’s minimum market value of listed securities (“MVLS”) requirement of $50 million. If our common stock is delisted from the Nasdaq Global Market, and our common stock is not accepted for listing on the Nasdaq Capital Market, the market price and liquidity of our common stock and our ability to raise additional capital would be adversely impacted. Our common stock is currently listed on the Nasdaq Global Market. Continued listing of a security on the Nasdaq Global Market is conditioned upon compliance with various continued listing standards. On July 15, 2026, we received a letter (the “Notice”) from the Nasdaq Stock Market (“Nasdaq”) notifying us that, for the 30-business day period ended July 14, 2026, we had not met the $50 million minimum market value of listed securities required to maintain continued listing on the Nasdaq Global Market as set forth in Nasdaq Marketplace Rule 5450(b)(2)(A) (the “MVLS Requirement”). As provided in the Nasdaq rules, we have 180 calendar days, or until January 11, 2027 (the “Compliance Date”), to regain compliance. To regain compliance, the market value of our listed securities must close at $50 million or more for a minimum of 10 consecutive business days at any time prior to January 11, 2027. In the event we do not regain compliance with the MVLS Requirement prior to the Compliance Date or we are not able to continue to meet other continued listing standards, including the minimum bid price of $1.00, Nasdaq will notify us that our securities are subject to delisting, at which point we may appeal the delisting determination to a Nasdaq hearings panel or choose to seek a listing of our common stock on the Nasdaq Capital Market. The Notice has no effect at this time on the listing of the Company’s securities on Nasdaq Global Market. We intend to actively monitor our MVLS between now and the Compliance Date, and may, if appropriate, evaluate available options including applying for a transfer to The Nasdaq Capital Market to resolve the deficiency and regain compliance with the requirement. While we are exercising diligent efforts to maintain the listing of our securities on the Nasdaq, there can be no assurance that we will be able to regain or maintain compliance with Nasdaq Global Market listing standards or satisfy the requirements necessary to transfer the listing of our securities to the Nasdaq Capital Market. If our common stock were delisted from the Nasdaq, trading of our common stock would most likely take place on an over-the-counter market established for unlisted securities, such as the OTCQB Venture Market operated by OTC Markets Group. An investor would likely find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our common stock on an over-the-counter market, and many investors would likely not buy or sell our common stock due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or other reasons. In addition, as a delisted security, our common stock would be subject to SEC rules as a “penny stock,” which impose additional disclosure requirements on broker-dealers. The regulations relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors such as broker commissions generally representing a higher percentage of the price of a penny stock than of a higher-priced stock, would further limit the ability of investors to trade in our common stock. 26 Item 5. Other Information Rule 10b5-1 Trading Plans During the three months ended June 30, 2026, no director or officer of the Company adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K. Item 6. Exhibits The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth below. Exhibit No. Description 3.1 Sixth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on August 14, 2024) 3.2 Amended and Restated Bylaws of Actuate Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on August 14, 2024) 31.1* Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended 31.2* Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended 32.1* Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS* XBRL Instance Document 101.SCH* XBRL Schema Document 101.CAL* XBRL Calculation Linkbase Document 101.DEF* XBRL Definition Linkbase Document 101.LAB* XBRL Label Linkbase Document 101.PRE* XBRL Presentation Linkbase Document * Filed herewith. 27 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized. Dated: August 14, 2026 ACTUATE THERAPEUTICS, INC. /s/ Daniel Schmitt Daniel Schmitt, President and Chief Executive Officer, Director (Principal Executive Officer) Dated: August 14, 2026 ACTUATE THERAPEUTICS, INC. /s/ Paul Lytle Paul Lytle, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) 28